Form 4 for SOPH SOPHiA GENETICS SA
Accepted 2026-04-03 06:59:26 ET · period of report 2026-04-02 · accession 0001840706-26-000090 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-03 06:59 | 2026-04-02 | SOPH | Menu Philippe | Chief Medical Off | A - Grant | $0.00 | +112.9K | 112.9K | New | $0 |
| D | 2026-04-03 06:59 | 2026-04-02 | SOPH | Menu Philippe | Chief Medical Off | A - Grant | $0.00 | +164.7K | 164.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-04-02 | A | A | 112,936 | $0.00 | 112,936 | D | — | — | (F1) Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. |
| 2 | Derivative | Share Option (Right to Buy) | 2026-04-02 | A | A | 164,671 | $0.00 | 164,671 | D | $5.04 · — to 2036-04-02 | 164,671 Ordinary Shares | (F2) The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030. |